Hashimoto Koji, Nio Yoshinori, Koike Makoto, Itakura Masayuki, Yano Seiji, Higami Tetsuya
Dept. of Cardiovascular and Digestive Surgery, Shimane University School of Medicine.
Gan To Kagaku Ryoho. 2004 Sep;31(9):1391-3.
A 43-year-old woman underwent breast-conserving therapy for right breast cancer with multiple liver metastases (pT3N3aM1, stage IV, ER (-), PgR (-), HER2 (3+)), in November, 2002. Following surgery, she received combination chemotherapy using hepatic arterial infusion of docetaxel and systemic administration of trastuzumab weekly. During therapy, no serious side effects and only grade 1 nausea were observed; after 3 courses, therapy was safely continued on an outpatient basis. Metastatic liver tumors responded to the treatment, and they completely disappeared on an abdominal CT 5 months later. In addition, all elevated tumor markers in serum decreased to the normal range. No new metastatic or recurrent lesions were found 14 months after surgery. We conclude that this combination chemotherapy is safe and may be very useful for the treatment of breast cancer patients with liver metastasis.
2002年11月,一名43岁女性因右乳癌伴多发肝转移(pT3N3aM1,IV期,ER(-),PgR(-),HER2(3+))接受了保乳治疗。术后,她接受了多西他赛肝动脉灌注联合曲妥珠单抗每周全身给药的联合化疗。治疗期间,未观察到严重副作用,仅出现1级恶心;3个疗程后,治疗安全地转为门诊治疗。转移性肝肿瘤对治疗有反应,5个月后腹部CT显示肿瘤完全消失。此外,血清中所有升高的肿瘤标志物均降至正常范围。术后14个月未发现新的转移或复发病灶。我们得出结论,这种联合化疗是安全的,可能对治疗肝转移乳腺癌患者非常有用。